ijms-logo

Journal Browser

Journal Browser

Novel Biomarkers and Emerging Therapeutic Targets for Breast and Gynecologic Cancers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 30 January 2026 | Viewed by 390

Special Issue Editor

Special Issue Information

Dear Colleagues,

Breast and gynecologic cancers continue to pose significant global health burdens, accounting for substantial morbidity and mortality among women worldwide. Despite the progress in diagnostic and therapeutic strategies, challenges remain in predicting disease progression and patient outcomes. The rapid expansion of molecular pathology has provided valuable insights into the pathogenesis of these malignancies, highlighting the important role of genetic, epigenetic, and transcriptomic alterations in shaping the tumor behavior. This Special Issue, entitled “Novel Biomarkers and Emerging Therapeutic Targets for Breast and Gynecologic Cancers,” aims to explore the interface between molecular pathology and clinical practice. We welcome contributions that identify novel biomarkers with diagnostic or prognostic value, as well as those that uncover emerging molecular targets with potential therapeutic applications. Particular emphasis will be placed on translational research that bridges the gap between molecular discoveries and real-world implementation in pathology and oncology. We invite researchers in molecular biology, cancer genomics, pathology, oncology, and related fields to submit original research articles, comprehensive reviews, and insightful perspectives that advance our understanding of breast and gynecologic cancers—including, but not limited to, breast, endometrial, ovarian, cervical, vaginal, vulvar, and fallopian tube carcinomas. We look forward to your valuable contributions to this timely and impactful Special Issue.

Dr. Hisham Bahmad
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • uterus
  • cervix
  • breast
  • ovary
  • endometrial cancer
  • ovarian cancer
  • cervical cancer
  • breast cancer
  • biomarkers
  • therapeutic target
  • personalized medicine
  • targeted therapy
  • molecular signatures
  • diagnosis
  • prognosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 2208 KB  
Review
Beyond the Microscope: Integrating Liquid Biopsies into the Molecular Pathology Era of Endometrial Cancer
by Miguel Perez, Luis Lorenzo Carvajal, Andres Wong, Robert Poppiti, Roberto Ruiz-Cordero, Amilcar A. Castellano-Sánchez and Hisham F. Bahmad
Int. J. Mol. Sci. 2025, 26(16), 7987; https://doi.org/10.3390/ijms26167987 - 19 Aug 2025
Viewed by 264
Abstract
Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries, with a growing incidence and significant molecular heterogeneity that challenges traditional diagnostic and management paradigms. While histopathological assessment remains the gold standard for diagnosis, emerging liquid biopsy technologies provide promising non-invasive [...] Read more.
Endometrial cancer (EC) is the most common gynecologic malignancy in developed countries, with a growing incidence and significant molecular heterogeneity that challenges traditional diagnostic and management paradigms. While histopathological assessment remains the gold standard for diagnosis, emerging liquid biopsy technologies provide promising non-invasive alternatives for tumor detection, molecular profiling, and disease monitoring. This review comprehensively explores the current landscape and clinical utility of liquid biopsy analytes—including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular RNAs, and exosomes—in the context of EC. We discuss the evolving role of pathologists in integrating molecular data with histomorphological features to enhance diagnostic precision, prognostic stratification, and therapeutic decision-making. Novel technologies such as methylation-based assays, tumor-informed ctDNA sequencing, and tumor-educated platelets (TEPs) are highlighted for their diagnostic accuracy and potential for early detection. Furthermore, we summarize key clinical trials and future directions aimed at validating liquid biopsy platforms for routine clinical implementation. As EC care transitions toward a precision oncology model, the integration of liquid biopsy with traditional surgical pathology offers a transformative approach to individualized and personalized patient management. Full article
Show Figures

Figure 1

Back to TopTop